University of Tsukuba and Astellas Pharma Inc. announced that they have signed a letter of confirmation regarding a strategic partnership to accelerate the digitalization of the drug discovery research field, as well as the development of the life science ecosystem in Tsukuba and Kashiwa-no-ha, and to further accelerate innovative drug discovery research and development.
Under this agreement, the two parties will exchange information on and discuss:
Promotion of drug discovery and other research, and creation of new startups through industry-academia collaboration between the two parties
Utilization of cutting-edge research equipment, drug discovery-related data and research seeds mutually owned by the two parties
Implementation of discussions and seminars to accelerate and develop collaborative research already conducted by the two parties
Promotion of drug discovery research and creation of new startups through exchange and communication with third-party venture company innovators in residence at SakuLab™-Tsukuba*1
Based on this agreement, the University of Tsukuba will establish an office in Astellas' SakuLab™-Tsukuba for the Tsukuba Digital-Bio International Center*2, where they are participating as a lead organization. The center will provide an environment where researchers from different fields including researchers specializing in medicine, biotechnology, and the AI/digital analytics field from the University of Tsukuba and Astellas' researchers specializing in drug discovery can discuss freely and energetically, aiming to create a place for innovative and active co-creative research through the fusion of different fields.
Astellas has already reflected the impact from this agreement in its financial forecast of the current fiscal year ending March 31, 2024.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!